NZ292289A - Spiro-azabicyclic compounds useful in treating cns disorder - Google Patents
Spiro-azabicyclic compounds useful in treating cns disorderInfo
- Publication number
- NZ292289A NZ292289A NZ292289A NZ29228995A NZ292289A NZ 292289 A NZ292289 A NZ 292289A NZ 292289 A NZ292289 A NZ 292289A NZ 29228995 A NZ29228995 A NZ 29228995A NZ 292289 A NZ292289 A NZ 292289A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- azabicyclo
- enantiomer
- spiro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9417084A GB9417084D0 (en) | 1994-08-24 | 1994-08-24 | Compounds useful in therapy |
GBGB9504627.2A GB9504627D0 (en) | 1995-03-08 | 1995-03-08 | Compounds for use in therapy |
PCT/SE1995/000937 WO1996006098A1 (en) | 1994-08-24 | 1995-08-22 | Spiro-azabicyclic compounds useful in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ292289A true NZ292289A (en) | 1998-05-27 |
Family
ID=26305509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ292289A NZ292289A (en) | 1994-08-24 | 1995-08-22 | Spiro-azabicyclic compounds useful in treating cns disorder |
Country Status (34)
Country | Link |
---|---|
US (2) | US5902814A (pl) |
EP (1) | EP0777671B1 (pl) |
JP (1) | JP3708962B2 (pl) |
KR (1) | KR100366331B1 (pl) |
CN (2) | CN1056846C (pl) |
AR (1) | AR031828A2 (pl) |
AT (1) | ATE192157T1 (pl) |
AU (1) | AU690735B2 (pl) |
BR (1) | BR9508751A (pl) |
CA (1) | CA2196995C (pl) |
CZ (1) | CZ289512B6 (pl) |
DE (1) | DE69516524T2 (pl) |
DK (1) | DK0777671T3 (pl) |
EE (1) | EE03399B1 (pl) |
EG (1) | EG24222A (pl) |
ES (1) | ES2145922T3 (pl) |
FI (1) | FI112868B (pl) |
GR (1) | GR3033878T3 (pl) |
HK (1) | HK1010370A1 (pl) |
HU (1) | HUT77352A (pl) |
IL (1) | IL115039A (pl) |
IS (1) | IS1852B (pl) |
MX (1) | MX9701292A (pl) |
NO (1) | NO307707B1 (pl) |
NZ (1) | NZ292289A (pl) |
PL (1) | PL183933B1 (pl) |
PT (1) | PT777671E (pl) |
RU (1) | RU2148058C1 (pl) |
SA (1) | SA95160370B1 (pl) |
SK (1) | SK282366B6 (pl) |
TR (1) | TR199501053A2 (pl) |
TW (1) | TW397837B (pl) |
UA (1) | UA54375C2 (pl) |
WO (1) | WO1996006098A1 (pl) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6277870B1 (en) * | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
JP4564135B2 (ja) * | 1999-07-26 | 2010-10-20 | 住友化学株式会社 | 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶 |
AU2001241056A1 (en) * | 2000-03-09 | 2001-09-17 | Mitsubishi Pharma Corporation | Spiro compounds, process for preparing the same and use thereof as drugs |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
JP2004507549A (ja) * | 2000-08-28 | 2004-03-11 | コロラド ステート ユニバーシティー リサーチ ファウンデーション | オキサゾリジノン部分を含む化合物およびその使用方法 |
US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
US20040259909A1 (en) * | 2001-10-16 | 2004-12-23 | Mccarthy Dennis | Treatment of fibromyalgia syndrome |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
US7273872B2 (en) * | 2002-12-06 | 2007-09-25 | The Feinstein Institute For Medical Research | Inhibition of inflammation using α 7 receptor-binding cholinergic agonists |
EP1654264A1 (en) * | 2003-07-08 | 2006-05-10 | AstraZeneca AB | Spiro [1-azabicyclo [2.2.2]octane-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
JP2008524208A (ja) * | 2004-12-15 | 2008-07-10 | アストラゼネカ・アクチエボラーグ | ニコチン性アセチルコリン受容体リガンド |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
EP2298410B1 (en) | 2004-12-27 | 2013-10-09 | The Feinstein Institute for Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
EP1833804A1 (en) * | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
US20100234349A1 (en) | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
DE102008015999B4 (de) | 2008-03-27 | 2011-04-21 | Novar Gmbh | Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
EA201001889A1 (ru) | 2008-06-20 | 2011-08-30 | Астразенека Аб | Производные дибензотиазепина и их применение |
EP2355893B1 (en) | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Devices for optimizing electrode placement for anti-inflamatory stimulation |
CN105687190A (zh) | 2008-11-19 | 2016-06-22 | 福拉姆医药股份有限公司 | 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍 |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US8507516B2 (en) | 2009-10-28 | 2013-08-13 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
AU2010336337B2 (en) | 2009-12-23 | 2016-02-04 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US8481555B2 (en) | 2010-04-30 | 2013-07-09 | Bristol-Myers Squibb Company | Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
AU2011256287B2 (en) | 2010-05-17 | 2016-11-10 | Envivo Pharmaceuticals, Inc. | A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
CA2914263C (en) | 2013-06-21 | 2021-05-18 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US10661112B2 (en) | 2016-07-25 | 2020-05-26 | Tonal Systems, Inc. | Digital strength training |
US11745039B2 (en) | 2016-07-25 | 2023-09-05 | Tonal Systems, Inc. | Assisted racking of digital resistance |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US10335626B2 (en) | 2017-10-02 | 2019-07-02 | Tonal Systems, Inc. | Exercise machine with pancake motor |
US10617903B2 (en) | 2017-10-02 | 2020-04-14 | Tonal Systems, Inc. | Exercise machine differential |
US10589163B2 (en) | 2017-10-02 | 2020-03-17 | Tonal Systems, Inc. | Exercise machine safety enhancements |
US10486015B2 (en) | 2017-10-02 | 2019-11-26 | Tonal Systems, Inc. | Exercise machine enhancements |
US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
US11285355B1 (en) | 2020-06-08 | 2022-03-29 | Tonal Systems, Inc. | Exercise machine enhancements |
US11878204B2 (en) | 2021-04-27 | 2024-01-23 | Tonal Systems, Inc. | First repetition detection |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH601304A5 (pl) * | 1974-02-12 | 1978-07-14 | Buskine Sa | |
US4028351A (en) * | 1971-09-07 | 1977-06-07 | Buskine S.A. | Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained |
GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
GB8816299D0 (en) * | 1988-07-08 | 1988-08-10 | Merck Sharp & Dohme | Therapeutic agents |
IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds |
US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
US5137895A (en) * | 1991-04-29 | 1992-08-11 | A. H. Robins Company, Incorporated | 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols |
-
1995
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active IP Right Cessation
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en active IP Right Grant
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 EP EP95930755A patent/EP0777671B1/en not_active Expired - Lifetime
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
-
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
-
1998
- 1998-09-26 HK HK98110995A patent/HK1010370A1/xx not_active IP Right Cessation
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
-
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
-
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU690735B2 (en) | Spiro-azabicyclic compounds useful in therapy | |
AU784400B2 (en) | New use and novel N-azabicyclo-amide derivatives | |
EP1213291B1 (en) | Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders | |
AU2005233492B2 (en) | Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor | |
AU706944B2 (en) | Azabicyclic esters of carbamic acids useful in therapy | |
EP0984970B1 (en) | Spiro-quinuclidine derivatives, their preparation and use | |
NZ529426A (en) | Spiroazabicyclic heterocyclic amine ligands for nicotinic acetylcholine receptors useful in therapy | |
JP2002114789A (ja) | アザビシクロアルカン誘導体とその治療的使用 | |
NZ540998A (en) | Novel diazabicyclic aryl derivatives | |
AU2003227522A1 (en) | 3-substituted quinuclidines and their use | |
US20070249588A1 (en) | Nicotinic Acetylcholine Receptor Ligands | |
AU2003222738B2 (en) | Novel azacyclic ethynyl derivatives | |
US7384954B2 (en) | 4-substituted imidazoles | |
US20070244097A1 (en) | Nicotinic AcetylcholineReceptor Ligands | |
NZ553277A (en) | Novel azabicyclic aryl derivatives and their medical use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
EXPY | Patent expired |